Calliditas announces commercial availability of Tarpeyo in USA

28 January 2022

Following approval of its drug by the US Food and Drug Administration in December, Swedish biotech firm Calliditas Therapeutics (STO: CALTX) today announced the commercial availability and initial sales of Tarpeyo (budesonide), the first and only FDA approved treatment for the immunoglobulin A nephropathy (IgA) patients at risk of disease progression.

Analysts have forecast that Tarpeyo, the company’s lead product candidate, could have global blockbuster potential, with peak sales in excess of $1 billion. Calliditas shares were up 3.5% a/t 95.70 Swedish kronor this morning.

“Our team has been working diligently to make Tarpeyo available to patients as quickly as possible. That we have already started shipping product speaks to providers’ desire for additional treatment options, underscoring the significant unmet need in this indication,” said Andrew Udell, president North America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK